Effects of Mifepristone in People With Difficult-to-Control T2D and Hypercortisolism on GLP-1 RAs
Saturday, June 6, 2026 1 min read
Key Takeaway: The presentation titled 'Effects of Mifepristone in People With Difficult-to-Control T2D and Hypercortisolism on GLP-1 RAs' was delivered by Dr. Lance A. Sloan at the American Diabetes Association Scientific Sessions on June 6, 2026. It discusses the impact of mifepristone on patients struggling with type 2 diabetes and hypercortisolism, particularly in relation to GLP-1 receptor agonists.
Price reaction · baseline $72.62 (2026-06-05 close) · 1 other CORT headline(s) in the window, move may be shared
day 0 close · peak
+1%
Market Sentiment Analysis
POSITIVE FACTORS
Presentation at a reputable scientific event.
Focus on a relevant therapeutic area: T2D and hypercortisolism.
Potential implications for treatment with GLP-1 RAs.
Full Press Release Details
Presented : American Diabetes Association Scientific Sessions , 6 June 2026, New Orleans, LA
Presenter : Lance A. Sloan , MD
Scientific journal publications or scientific congress presentations may include information regarding investigational products or uses.
Download Presentation
The post Effects of Mifepristone in People With Difficult-to-Control T2D and Hypercortisolism on GLP-1 RAs appeared first on Corcept Therapeutics .
Frequently Asked Questions
What was the focus of the presentation?
The presentation focused on the effects of mifepristone in patients with difficult-to-control T2D and hypercortisolism.
Who presented the findings?
The findings were presented by Dr. Lance A. Sloan.
When and where was the presentation held?
The presentation took place on June 6, 2026, at the American Diabetes Association Scientific Sessions in New Orleans.
What is the relevance of GLP-1 RAs in this context?
The presentation discusses the implications of mifepristone on GLP-1 receptor agonists for treating T2D.